Paliperidona Tad Tad Pharma (Paliperidone)

Paliperidone, the active ingredient in Paliperidona Tad Tad Pharma, is an atypical antipsychotic presented as a tablet for oral use, available in various strengths. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adults.

GNH USA supplies Paliperidona Tad Tad Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is used within the psychotic disorder therapeutic pathway to manage core symptoms of schizophrenia and related conditions.

Schizophrenia: reduces psychotic symptoms and lowers risk of relapse. Schizoaffective disorder: improves both mood and psychotic features. Maintenance therapy: helps sustain stability in patients who have achieved symptom control.

Paliperidone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Weight gain: increase in body mass index. - Somnolence: feeling unusually sleepy. - Akathisia: inner restlessness and urge to move. - Extrapyramidal symptoms: muscle stiffness or tremor. - Elevated prolactin: menstrual changes or galactorrhea. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Tardive dyskinesia: involuntary, repetitive movements. - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Seizures: risk of convulsive episodes. - Severe orthostatic hypotension: marked drop in blood pressure upon standing. - Myocarditis or cardiomyopathy: inflammation of heart muscle. - Agranulocytosis: dangerously low white blood cell count.

When prescribing paliperidone, clinicians should observe several safety considerations.

Monitor metabolic parameters: track weight, glucose, and lipid levels. Assess extrapyramidal symptoms: watch for tremor, rigidity, or akathisia. Screen cardiovascular status: evaluate blood pressure and ECG for QT prolongation. Check prolactin‑related effects: inquire about menstrual irregularities or galactorrhea. Avoid use in patients with known hypersensitivity to paliperidone. Use caution in elderly with dementia-related psychosis due to increased mortality risk. Store at ambient temperature: keep in original container, protect from moisture.

Paliperidone can interact with several medications, affecting its plasma concentration or safety profile.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise paliperidone levels. - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower paliperidone exposure. - QT‑prolonging agents (e.g., erythromycin, haloperidol): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may mask extrapyramidal signs. - Other dopamine antagonists: can enhance side‑effect burden. - Alcohol or CNS depressants: may intensify sedation and dizziness.